Jill Murphy, Associate Editor

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being evaluated for the treatment of anemia of chronic kidney disease in adult patients on and not on dialysis.

Study shows combining brentuximab vedotin with the standard chemotherapy regimen reduced the risk of relapse in children with high-risk Hodgkin lymphoma by 10%.

Systemically administered hormonal therapy may be associated with a greater risk of depression before and during menopause.

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

Among nicotine users, there was an approximately 4 beat per minute jump in heart rate after vaping or smoking.

Investigational broadly neutralizing antibody shows promise as potential as a first-in-class treatment option for HIV.

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke.

Pre-planned safety reviews performed for the duration of the study found that the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

Herpes zoster can increase the risk of stroke, especially among patients under 40 years of age, for whom the vaccine is not typically recommended.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Otilimab also inhibits the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

The indication is approved under accelerated approval based on response rate, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

These study findings may have implications for monitoring for the development of ICANS in patients receiving CAR T-cell therapies for cancer, according to the authors.

Food insecurity has previously been linked to adverse cardiovascular outcomes, but research is limited regarding the local food environment and the association with death from heart failure.

The objective of the trial was to compare letermovir with valganciclovir in preventing CMV disease in adults who received a kidney transplant and who are at high risk for CMV disease.

People with anxiety and related disorders were found to have vaccine hesitancy related to concerns regarding adverse effects and efficacy.

Patients with synchronous liver metastases from colorectal cancer have been found to have worse outcomes than those with metachronous liver metastases.

Research shows that patients with a severe form of psoriasis have a higher risk of death from cardiovascular disease.

The efficacy of Shingrix was 97% in adults 50 years of age and older and 91% in adults 70 years of age and older over an extended follow-up period.

The treatment modulates the number of myosin heads that can enter “on actin” states and lowers the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Study finds daily supplementation with cod liver oil for 6 months during the SARS-CoV-2 pandemic did not reduce the incidence of SARS-CoV-2 infection.

There is currently no approved RSV vaccine despite ongoing research efforts.

Immune function has been found to play a significant role in multiple myeloma.

Novavax’s quadrivalent influenza vaccine candidate has previously induced cross-reactive polyfunctional CD4+ T-cell responses, according to a company press release.

The study confirmed that patients with psoriasis are considered to have an increased risk for both chronic kidney disease and ESRD, because inflammation plays a significant role in those conditions as well as heart disease.

The vaccine is in a ready-to-use liquid formulation in a vial containing 10 doses, with the vaccination regimen calling for a pair of 0.5 ml doses administered intramuscularly 21 days apart.

Previous studies have shown that PAD also impacts health status and functioning.